Abstract | OBJECTIVE: DATA SOURCES: Information was obtained from MEDLINE searches (1996-April 2002) of English-language medical literature. Search terms included CS-866, olmesartan, olmesartan medoxomil, RNH-6270 (active metabolite of olmesartan), Benicar, angiotensin receptors, and antihypertensive agents. In addition, references from relevant articles were reviewed for additional citations. The authors independently reviewed literature identified in the searches. Studies evaluating olmesartan (i.e., abstracts, clinical trials, data on file with manufacturer) were considered for inclusion. STUDY SELECTION: All articles identified from data sources with pertinent information regarding olmesartan medoxomil were evaluated, and all information deemed relevant was included in this review. DATA SYNTHESIS: CONCLUSIONS:
|
Authors | Stephanie F Gardner, Amy M Franks |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 37
Issue 1
Pg. 99-105
(Jan 2003)
ISSN: 1060-0280 [Print] United States |
PMID | 12503943
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
- Imidazoles
- Receptors, Angiotensin
- Tetrazoles
- Angiotensin II
- Olmesartan Medoxomil
|
Topics |
- Angiotensin II
(metabolism)
- Angiotensin Receptor Antagonists
- Antihypertensive Agents
(adverse effects, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Drug Interactions
- Humans
- Hypertension
(drug therapy, metabolism)
- Imidazoles
(adverse effects, pharmacology, therapeutic use)
- Olmesartan Medoxomil
- Prescription Fees
- Receptors, Angiotensin
(metabolism)
- Tetrazoles
(adverse effects, pharmacology, therapeutic use)
|